Loading cancer entity…
Loading cancer entity…
Clinical trials
210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (37)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03455270 | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | completed | Phase 1 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 21, 2026 | clinicaltrials |
| NCT03317405 | Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | active not recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT01791478 | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer | completed | Phase 1 | 46 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06218303 | Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ | recruiting | Phase 1 | 50 | Finn, Olivera, PhDOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05340673 | Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer | active not recruiting | Phase 1 | 208 | City of Hope Medical CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05900986 | LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Integro TheranosticsINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT02856503 | Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Eli Avisar, MDOTHER | 0 | Apr 17, 2026 | clinicaltrials |
| NCT02779855 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04144023 | A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ | recruiting | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07178665 | Pilot Trial of Preop Partial Radiation in Breast Cancer Patients | suspended | Phase 1 | 98 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT02876640 | Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer | terminated | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | terminated | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT02983071 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 4 | Feb 15, 2023 | clinicaltrials |
| NCT03323658 | Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT01023477 | Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) | completed | Phase 1 / Phase 2 | 12 | Inova Health Care ServicesOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT02061332 | DC Vaccine for Patients With Ductal Carcinoma In Situ(DCIS6) | completed | Phase 1 / Phase 2 | 58 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT02365714 | CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)(CK-SAPBI) | terminated | Phase 1 / Phase 2 | 2 | Georgetown UniversityOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT01372618 | Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor | terminated | Phase 1 / Phase 2 | 9 | NYU Langone HealthOTHER | 1 | Dec 27, 2017 | clinicaltrials |
| NCT00637481 | A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Dec 29, 2016 | clinicaltrials |
| NCT00573495 | Multipeptide Vaccine for Advanced Breast Cancer | completed | Phase 1 | 11 | University of PennsylvaniaOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT00637364 | High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain(HIFU Pancreas) | suspended | Phase 1 / Phase 2 | 5 | CMED HIFU Development CorporationINDUSTRY | 1 | Jan 13, 2009 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials